Abstract
In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.
Publication types
-
Clinical Trial
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents, Alkylating / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / administration & dosage
-
Drug Administration Schedule
-
Epirubicin / administration & dosage
-
Female
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Male
-
Melphalan / administration & dosage
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Myeloproliferative Disorders / chemically induced
-
Peptichemio / administration & dosage
-
Prednisone / administration & dosage
-
Recombinant Proteins
-
Vincristine / administration & dosage
Substances
-
Antineoplastic Agents, Alkylating
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Epirubicin
-
Vincristine
-
Cyclophosphamide
-
Peptichemio
-
Melphalan
-
Prednisone